# US 2024/0002803 A1 · Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002803 A1
- Document ID: US20240002803A1
- Status: Published application
- Kind: A1
- Application number: 18/219,802
- Filed: 2023-07-10
- Published: 2024-01-04
- Earliest claimed: 2021-01-10
- Assignees: SuperMeat the Essence of Meat Ltd.
- Applicants: SuperMeat the Essence of Meat Ltd.
- Inventors: Ido SAVIR; Tomer HALEVY; Yuval LEVY PERETZ
- Web page: https://patentgrep.com/patent/US20240002803A1

## CPC

- A23L 13/00: Meat products; Meat meal; Preparation or treatment thereof
- C12N 5/0653: {Adipocytes; Adipose tissue}
- A23L 33/17: Amino acids, peptides or proteins
- C12N 5/0031: {Serum-free culture media}
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0658: {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
- A23K 10/10: obtained by microbiological or biochemical processes (using chemicals or microorganisms for ensilaging of green fodder A23K30/15)
- A23K 10/20: from material of animal origin (obtained by microbiological or biochemical processes A23K10/10)
- C12N 2500/25: Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2500/30: Organic components
- C12N 2500/32: Amino acids
- C12N 2500/36: Lipids
- C12N 2500/74: from fungi, e.g. yeasts
- C12N 2500/76: from plants
- C12N 2500/92: Medium free of human- or animal-derived components
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/02: from embryonic cells
- C12N 2513/00: 3D culture
- C12N 2533/54: Collagen; Gelatin
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23K: FODDER

## Abstract

Primed cells, pluripotent stem cell aggregates and microtissues produced therefrom and uses of same for producing edible products.

## Claims

### Claim 1

A method of producing a microtissue comprising one or more cell types, the method comprising:
(a) forming in suspension, without matrix adherence, aggregates comprising non-human pluripotent stem cells, said non-human pluripotent stem cells of said aggregates exhibiting a doubling time of 10-20 hours in an undifferentiated manner for more than 60 passages, capable of differentiating into muscle, fat and connective tissue upon differentiation induction, growing in the presence of growth factors, exhibiting cell to cell adhesion lower than that of embryoid bodies (EBs) as determined by reduced expression of adhesion molecules selected from the group consisting of COL6A2, CD44, COL6A1, ANXA1, ANXA2 and S100A11 as compared to said EBs; and
(b) transferring the aggregates to a bioreactor for growth in suspension without matrix adherence in the absence of growth factors to thereby produce the microtissue.

### Claim 2

A method of producing a microtissue comprising one or more cell types, the method comprising:
(a) providing a suspension culture which comprises aggregates comprising non-human pluripotent stem cells, said non-human pluripotent stem cells of said aggregates exhibiting a doubling time of 10-20 hours in an undifferentiated manner for more than 60 passages, capable of differentiating into muscle, fat and connective tissue upon differentiation induction, growing in the presence of growth factors, exhibiting cell to cell adhesion lower than that of embryoid bodies (EBs) as determined by reduced expression of adhesion molecules selected from the group consisting of COL6A2, CD44, COL6A1, ANXA1, ANXA2 and S100A11 as compared to said EBs; and
(b) transferring the aggregates to a bioreactor for growth in suspension without matrix adherence in the absence of growth factors to thereby produce the microtissue.

### Claim 3 (depends on 1)

A method of producing a microtissue comprising one or more cell types of interest, the method comprising:
(a) producing the microtissue according to claim 1; and
(b) subjecting said microtissue to differentiation conditions in suspension to thereby produce the microtissue comprising one or more cell types of interest.

### Claim 4 (depends on 1)

The method of claim 1, wherein numerical values indicated are provided under optimal conditions for cell growth of a type and developmental stage as said non-human pluripotent stem cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein said non-human pluripotent stem cells are selected from the group of avian pluripotent stem cells, bovine pluripotent stem cells, porcine pluripotent stem cells, goat pluripotent stem cells, sheep pluripotent stem cells, shrimp pluripotent stem cells and fish pluripotent stem cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein said microtissue is 30-500 μm in diameter.

### Claim 7 (depends on 1)

The method of claim 1, wherein said non-human pluripotent stem cells of said aggregates exhibit alkaline phosphatase expression, exhibit telomerase gene expression and/or are SSEA4−, LIN28+, ENS-1+, NANOG+, OCT4,+ and TRA-1-60+.

### Claim 8 (depends on 1)

The method of claim 1, wherein said one or more cell types are selected from the group consisting of a muscle cell, a fat cell and a connective tissue cell.

### Claim 9 (depends on 1)

The method of claim 1, wherein said one or more cell types comprise a fat cell and a muscle cell.

### Claim 10 (depends on 1)

The method of claim 1, wherein said matrix adherence is selected from feeder cells and a native or synthetic matrix molecule.

### Claim 11 (depends on 10)

The method of claim 10, wherein said matrix molecule comprises gelatin.

### Claim 12 (depends on 1)

The method of claim 1, wherein each step of the method is devoid of animal components other than said non-human pluripotent stem cells.

### Claim 13 (depends on 1)

The method of claim 1, wherein said aggregates exhibit about the same gene expression as that of a stem cell line from which they are derived, excluding expression levels of cell motility and migration-related genes.

### Claim 14 (depends on 1)

The method of claim 1, wherein said microtissue is NANOG-OCT4− LIN28−, SSEA3+.

### Claim 15 (depends on 3)

The method of claim 3, wherein said subjecting said microtissue to differentiation conditions comprises priming said microtissues in the presence of fatty acids at a concentration not exceeding 100 μM for a time sufficient to obtain muscle cells and stem cells having an adipocyte fate while retaining a proliferative phenotype, optionally followed by differentiating in the presence of fatty acids at a concentration of 100 uM or above.

### Claim 16 (depends on 1)

The method of claim 1, wherein said doubling time is of no more than 12 hours.

### Claim 17 (depends on 2)

The method of claim 2, wherein said doubling time is of no more than 12 hours.

### Claim 18 (depends on 1)

A microtissue obtainable according to the method of claim 1.

### Claim 19

A microtissue comprising one or more cell types, said microtissue being 30-500 μm in diameter, wherein cells of said microtissue are NANOG-OCT4− LIN28−, SSEA3+, and wherein optionally said one or more cell types comprise a fat cell and a muscle cell.

### Claim 20 (depends on 19)

A food comprising the microtissue of claim 19.

### Claim 21 (depends on 19)

A method of producing food, the method comprising combining microtissue of claim 19 with an edible composition for human consumption.
